MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597614 | Name: Antagonist G

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Antagonist G is an anticancer peptide; a broad spectrum neuropeptide growth factor antagonist.

Chemical Structure

Antagonist G
Antagonist G
CAS#115150-59-9 (free base)

Theoretical Analysis

MedKoo Cat#: 597614

Name: Antagonist G

CAS#: 115150-59-9 (free base)

Chemical Formula: C49H66N12O6S

Exact Mass: 950.4949

Molecular Weight: 951.20

Elemental Analysis: C, 61.87; H, 6.99; N, 17.67; O, 10.09; S, 3.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
115150-59-9 (free base) Antagonist G TFA
Synonym
Antagonist G; Arg-trp-N-methyl-phe-trp-leu-met-NH2;
IUPAC/Chemical Name
(S)-N-((5S,8S,11R,14S,17R)-11-((1H-indol-3-yl)methyl)-14-benzyl-5-carbamoyl-18-(1H-indol-3-yl)-8-isobutyl-15-methyl-7,10,13,16-tetraoxo-2-thia-6,9,12,15-tetraazaoctadecan-17-yl)-2-amino-5-guanidinopentanamide
InChi Key
CUCSSYAUKKIDJV-FAXBSAIASA-N
InChi Code
InChI=1S/C49H66N12O6S/c1-29(2)23-39(45(64)57-38(43(51)62)20-22-68-4)58-46(65)40(25-31-27-55-36-18-10-8-15-33(31)36)59-47(66)42(24-30-13-6-5-7-14-30)61(3)48(67)41(26-32-28-56-37-19-11-9-16-34(32)37)60-44(63)35(50)17-12-21-54-49(52)53/h5-11,13-16,18-19,27-29,35,38-42,55-56H,12,17,20-26,50H2,1-4H3,(H2,51,62)(H,57,64)(H,58,65)(H,59,66)(H,60,63)(H4,52,53,54)/t35-,38-,39-,40+,41+,42-/m0/s1
SMILES Code
[H]N[C@H](C(N[C@@H](C(N([C@H](C(N[C@@H](C(N[C@H](C(N[C@H](C(N)=O)CCSC)=O)CC(C)C)=O)CC1=CNC2=C1C=CC=C2)=O)CC3=CC=CC=C3)C)=O)CC4=CNC5=C4C=CC=C5)=O)CCCNC(N)=N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 951.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: MacKinnon AC, Waters C, Rahman I, Harani N, Rintoul R, Haslett C, Sethi T. [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy. Br J Cancer. 2000 Oct;83(7):941-8. PubMed PMID: 10970698; PubMed Central PMCID: PMC2374683. 2: Clive S, Webb DJ, MacLellan A, Young A, Byrne B, Robson L, Smyth JF, Jodrell DI. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res. 2001 Oct;7(10):3071-8. PubMed PMID: 11595697. 3: Moreira JN, Gaspar R. Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer. Braz J Med Biol Res. 2004 Aug;37(8):1185-92. Epub 2004 Jul 20. PubMed PMID: 15273819. 4: Jones DA, Cummings J, Langdon SP, Smyth JF. Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Gen Pharmacol. 1997 Feb;28(2):183-9. Review. PubMed PMID: 9013192. 5: Cummings J, MacLellan AJ, Jones DA, Langdon SP, Rozengurt E, Ritchie AA, Smyth JF. Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograft. Ann Oncol. 1995 Jul;6(6):595-602. PubMed PMID: 8573540. 6: MacKinnon AC, Armstrong RA, Waters CM, Cummings J, Smyth JF, Haslett C, Sethi T. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Br J Cancer. 1999 Jun;80(7):1026-34. PubMed PMID: 10362111; PubMed Central PMCID: PMC2363053. 7: Moreira JN, Hansen CB, Gaspar R, Allen TM. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim Biophys Acta. 2001 Oct 1;1514(2):303-17. PubMed PMID: 11557029. 8: Jones DA, Cummings J, Langdon SP, MacLellan AJ, Higgins T, Rozengurt E, Smyth JF. Metabolism of the anticancer peptide H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2. Peptides. 1995;16(5):777-83. PubMed PMID: 7479315. 9: Reubsaet JL, Beijnen JH, Bult A, Hop E, Vermaas R, Kellekule Y, Kettenes-van den Bosch JJ, Underberg WJ. Structural identification of the degradation products of the antitumor peptide antagonist [Arg6,D-Trp7,9,MePhe8]substance P (6-11). Anal Chem. 1995 Dec 1;67(23):4431-6. PubMed PMID: 8633781. 10: Jones DA, Cummings J, Langdon SP, MacLellan A, Smyth JF. Characterization of the deamidase enzyme responsible for the metabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2. Biochem Pharmacol. 1995 Aug 25;50(5):585-90. PubMed PMID: 7669060. 11: Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett. 2002;7(2):217-9. PubMed PMID: 12097921. 12: Smyth JF. Cancer genetics and cell and molecular biology. Is this the way forward? Chest. 1996 May;109(5 Suppl):125S-129S. PubMed PMID: 8635390.

View History

Pobilukast edamine anhydrous

Pobilukast edamine anhydrous